Department of Dermatology, Massachusetts General Hospital, Boston, Massachusetts, USA.
Harvard Medical School, Boston, Massachusetts, USA.
Oncologist. 2021 May;26(5):e898-e901. doi: 10.1002/onco.13768. Epub 2021 Apr 17.
The aim of this study was to determine the rate of coronavirus disease-19 (COVID-19) among patients with cancer treated with immune checkpoint inhibitors (ICIs).
This was a retrospective study of 1,545 patients with cancer treated with ICIs between July 1, 2019, and February 29, 2020, and 20,418 age-, sex-, and cancer category-matched controls in a large referral hospital system. Confirmed COVID-19 case and mortality data were obtained with Massachusetts Department of Public Health from March 1 through June 19, 2020.
The mean age was 66.6 years, and 41.9% were female. There were 22 (1.4%) and 213 (1.0%) COVID-19 cases in the ICI and control groups, respectively. When adjusting for demographics, medical comorbidities, and local infection rates, ICIs did not increase COVID-19 susceptibility.
ICIs did not increase the rate of COVID-19. This information may assist patients and their oncologists in decision-making surrounding cancer treatment during this pandemic.
本研究旨在确定接受免疫检查点抑制剂 (ICI) 治疗的癌症患者中 COVID-19 的发病率。
这是一项回顾性研究，纳入了 2019 年 7 月 1 日至 2020 年 2 月 29 日在一家大型转诊医院系统中接受 ICI 治疗的 1545 例癌症患者和 20418 例年龄、性别和癌症分类匹配的对照者。COVID-19 确诊病例和死亡率数据来自马萨诸塞州公共卫生部，时间为 2020 年 3 月 1 日至 6 月 19 日。
平均年龄为 66.6 岁，41.9%为女性。ICI 组和对照组分别有 22 例（1.4%）和 213 例（1.0%）COVID-19 病例。在调整了人口统计学、合并症和当地感染率后，ICI 并未增加 COVID-19 的易感性。
ICI 并未增加 COVID-19 的发病率。这些信息可能有助于患者及其肿瘤学家在这一大流行期间制定癌症治疗决策。
